Nektar Announces Definitive Agreement with Ampersand …

SAN FRANCISCO , Nov. 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat …

8%
OFF

Nektar Sells Its PEGylation Reagent Manufacturing Business

2 weeks from now

Nov 5, 2024 · California, USA-based biotech Nektar Therapeutics’ (Nasdaq: NKTR) shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing …

thepharmaletter.com

$90
OFF

Nektar Therapeutics Reports Third Quarter 2024 Financial …

2 weeks from now

In November, Nektar announced a definitive agreement with Ampersand Capital Partners to sell its commercial PEGylation manufacturing business in Huntsville, Alabama for $90 million in …

nektar.com

$6.66
OFF

Revance Therapeutics: The Takeover Saga Continues As Teoxane …

2 weeks from now

1 day ago · Revance Therapeutics, Inc. faces financial struggles and competition, leading to a proposed takeover by Crown Labs, initially valued at $6.66 per share, later reduced to $3.10. …

seekingalpha.com

FAQs about Nektar Announces Definitive Agreement with Ampersand … Coupon?

Who is Nektar Therapeutics?

Nektar (NKTR) Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and reagent supply business to Ampersand Capital Partners, a Boston-based private equity firm. ...

What is Nektar Therapeutics' new strategic plan?

Nektar Therapeutics (Nasdaq: NKTR) today announced a new strategic plan focused on prioritizing key research and development efforts, including NKTR-358, NKTR-255, and several core research programs. ...

How many employees does Nektar Therapeutics have?

Nektar Therapeutics is a biotechnology and pharmaceutical company specializing in investigational medicines with 501–1,000 employees. The firm provides services to several health care sectors, such as oncology, immunology, and virology. Office location: San Francisco, California. ...

Did ampersand buy Nektar?

Ampersand has agreed to acquire Nektar’s commercial-scale manufacturing facility and PEGylation reagent supply business for a total consideration of $90M, comprised of $70M in cash proceeds and $20M in a retained equity position for Nektar in a newly-created Ampersand portfolio company. ...

Who is Nektar Therapeutics (India) Private Limited?

Nektar Therapeutics (India) Private Limited is a company with CIN number U24239TG2005FTC046253 and registration number 46253. Its email address is [email protected] and its registered address is Sy.No. 101/2, Lalgadimalakpet Genome Valley, Shamirpet Hyderabad TG 500078 IN. ...

How much money did Nektar receive from a strategic divestment?

Nektar to receive $90 million in total consideration for the business, comprised of $70 million in cash and $20 million equity ownership in new portfolio company. Strategic divestiture allows Nektar to streamline its operations and continue its strategic focus on the development of core R&D programs in immunology. ...